PBI-4050

February 21, 2018February 21, 2018

Prometic’s PBI-4050 Regulates 2 Receptors Key to Fibrosis Development, Study Shows

PBI-4050, Prometic Life Sciences’ lead small molecule therapy candidate, targets a new antifibrotic pathway involving two receptors that play opposite roles in fibrosis development, researchers found. The study, “A Newly Discovered ... Read more

February 2, 2018February 2, 2018

FDA Approves Phase 3 Trial Plan for Prometic’s Pulmonary Fibrosis Therapy

Idiopathic Pulmonary Fibrosis, News

The U.S. Food and Drug Administration has approved Prometic Life Sciences’ plan for a Phase 3 pivotal trial of its idiopathic pulmonary fibrosis therapy PBI-4050. PBI-4050 is an oral compound designed to ... Read more

December 22, 2017December 22, 2017

FDA Grants Orphan Drug Status to Pulmonary Fibrosis Therapy Candidate Ryplazim

Idiopathic Pulmonary Fibrosis, News

The U.S. Food and Drug Administration has granted orphan drug status to Ryplazim, an idiopathic pulmonary fibrosis therapy that Prometic Life Sciences is developing. It’s the second time the FDA has designated a Prometic IPF ... Read more

December 15, 2017December 15, 2017

Britain Designates Prometic’s IPF Therapy a Promising Innovative Medicine

Idiopathic Pulmonary Fibrosis

British regulators have designated Prometic Life Sciences’ pulmonary fibrosis therapy PBI-4050 a Promising Innovative Medicine, the first step toward allowing some patients to obtain it before it is approved. Prometic developed the oral drug candidate ... Read more

November 1, 2017November 1, 2017

Prometic’s Pulmonary Fibrosis Therapy PBI-4050 Earns FDA Fast Track Status

Idiopathic Pulmonary Fibrosis

The U.S. Food and Drug and Drug Administration has awarded Fast Track status to PBI-4050, Prometic Life Sciences‘ treatment for lung scarring in idiopathic pulmonary fibrosis. The Fast Track designation ... Read more

October 2, 2017October 2, 2017

Prometic Gets FDA Approval to Start Phase 2/3 Trial of PBI-4050 in IPF Patients

Idiopathic Pulmonary Fibrosis, News

Prometic Life Sciences announced that PBI-4050, its investigational therapy for idiopathic pulmonary fibrosis (IPF), has been cleared by the U.S. Food and Drug Administration (FDA) to enter a Phase 2/3 combination-treatment trial in the ... Read more

August 21, 2017August 21, 2017

Prometic, SRAM to Jointly Advance 3 Fibrosis, Scleroderma Therapies for Booming Chinese Market

Idiopathic Pulmonary Fibrosis, News

Canada’s Prometic Life Sciences and Shenzhen Royal Asset Management (SRAM) will jointly manufacture, develop and commercialize three fibrosis and scleroderma therapies in China, the two companies announced. namely the drugs PBI-4050, PBI-4547 and PBI-4425. A new subsidiary, ... Read more

April 19, 2017April 19, 2017

FDA Agrees with ProMetic’s Protocol for PBI-4050 in IPF Clinical Trials

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences recently announced that the U.S. Food and Drug Administration (FDA) agreed with the design of the first Phase 2/3 clinical trials evaluating PBI-4050 for idiopathic pulmonary fibrosis (IPF) ... Read more

February 28, 2017February 28, 2017

Phase 2 Trial Results Show Promise for ProMetic’s IPF Therapy Candidate

Idiopathic Pulmonary Fibrosis, News

The completed Phase 2 clinical study evaluating ProMetic’s PBI-4050 in people with idiopathic pulmonary fibrosis (IPF) demonstrated positive trial results of the drug’s effectiveness and tolerability as a monotherapy and ... Read more

November 18, 2016November 18, 2016

ProMetic’s Therapy Improved Fibrosis, Cardiac Function in Mice with Heart Failure

News, Pulmonary Hypertension

ProMetic Life Science’s fibrosis-targeting investigational drug PBI-4050 improved pulmonary hypertension (PH), lung remodeling and right ventricular function in mice with heart failure. PBI-4050 also decreased biomarkers for heart disease in patients with ... Read more